NIH Funds Pivotal Drug Research for Vertex Pharmaceuticals
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
The National Institutes of Health provided funding for pivotal drug development research with Vertex Pharmaceuticals on October 14, 2026. Vertex Pharmaceuticals has developed several drugs for cystic fibrosis, including Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek. Before 2012, there was no treatment for cystic fibrosis, and the median age of death was 15.
From miragenews.com
Why it matters
The funding supports research into cystic fibrosis, a condition for which Vertex Pharmaceuticals has created several successful treatments. This NIH funding validates the foundational science required for CF drug development by Vertex Pharmaceuticals.
From miragenews.com
Who's involved
- National Institutes of HealthProvided funding for pivotal drug development research.
- Vertex PharmaceuticalsReceived funding and is a developer of cystic fibrosis drugs.
Keep exploring
The entities involved
-
National Institutes of Health
government organization in Shah Alam, Malaysia
-
Vertex Pharmaceuticals
American pharmaceutical company